Associate Director, Qualified Person, Europe

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Qualified Person (QP) holds ultimate responsibility for the certification and release of medicinal products in accordance with EU GMP, Directive 2001/83/EC, Dutch pharmaceutical legislation, and applicable Marketing Authorisations. The role provides independent, authoritative quality leadership across site operations and serves as a key member of the site leadership team, ensuring patient safety, product quality, regulatory compliance, and reliable supply. In addition to batch release accountability, the QP provides strategic oversight of the Pharmaceutical Quality System, partners closely with senior stakeholders across Quality, Technical Operations, Supply Chain, and Regulatory Affairs, and represents the site in interactions with Health Authorities. Regulatory Accountability & Product Release Act as the legally registered Qualified Person with full authority for certification and release of clinical and commercial medicinal products. Ensure batch certification in compliance with EU GMP, Directive 2001/83/EC, national legislation, EU GMP Annex 16, the applicable Marketing Authorisation, and approved regulatory dossiers (e.g., MA, IMPD), and applicable authorisations. Exercise independent decision-making authority, including batch rejection and escalation when required. Ensure timely batch disposition aligned with supply commitments and compliance requirements. Responsible for the certification and release of Investigational Medicinal Products (IMPs) in accordance with EU Clinical Trial Regulation and EU GMP Annex 13, including oversight of randomisation, blinding, labelling, comparators, and clinical supply chain integrity. Maintain QP oversight of the end‑to‑end GMP supply chain, including qualification, approval, and ongoing monitoring of contract manufacturers, testing laboratories, API suppliers, and logistics providers. Quality System Leadership Provide oversight of the Pharmaceutical Quality System, ensuring inspection readiness and regulatory alignment. Oversee deviations, CAPAs, change controls, investigations, complaints, and recalls. Approve critical GMP documentation including SOPs, validation documentation, and quality agreements. Ensure that third‑country manufacturing sites comply with EU GMP requirements, including audit strategy, GMP equivalence assessment, and importation controls. Provide QP oversight of data integrity governance across GMP processes and computerized systems, ensuring adherence to ALCOA+ principles, validated system use, appropriate audit trails, and timely escalation of data integrity risks that may impact batch certification or regulatory complian Oversee continued process and product verification activities, including stability programs, ongoing trend analysis, and Product Quality Reviews (PQR/APQR), ensuring that emerging quality risks are identified, assessed, and managed proactively throughout the product lifecycle. Strategic & Cross-Functional Leadership Act as a strategic quality partner to site and functional leadership. Lead quality risk assessments related to manufacturing operations and change initiatives. Mentor QA professionals and support QP succession and capability building. Embed a proactive quality culture